Sparks commentary - Newron Pharmaceuticals

Healthcare

Sparks - Newron Pharmaceuticals

More on this equity
Newron Pharmaceuticals (SIX: NWRN) announces new evenamide patent
Published by Arron Aatkar, PhD

Newron Pharmaceuticals has announced a new composition of matter patent for its lead schizophrenia candidate, evenamide. The patent was issued by the European Patent Office and claims crystalline forms of the drug candidate, processes for its preparation and its uses. The patent should provide protection to 2044.

Evenamide is currently being evaluated in the registrational Phase III ENIGMA programme, which has been designed to enrol at least 1,000 schizophrenia patients. Top-line results are expected in Q426, representing a significant upcoming inflection point for the company.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.